Information of surgery and anesthesia [n(%)]. by Qingwen Cao (22439195)

“…</p><p>Results</p><p>In the YO, MO, and OO groups, the male-to-female ratios were 1:2.1, 1:1.8, and 1:2.3, respectively (<i><i>P</i> </i>=<i> </i>0.293). The proportion of patients with American Society of Anesthesiologists (ASA) ≥ III, Nottingham hip fracture score (NHFS) ≥ 5 and preoperative activity tolerance < 4 metabolic equivalents (METs) increased sequentially (<i><i>P</i> </i>< 0.001), across the YO, MO, and OO groups, whereas the proportion of those with three or more internal medicine comorbidities sequentially decreased (<i><i>P</i> </i>< 0.001). …”

Raw data. by Qingwen Cao (22439195)

“…</p><p>Results</p><p>In the YO, MO, and OO groups, the male-to-female ratios were 1:2.1, 1:1.8, and 1:2.3, respectively (<i><i>P</i> </i>=<i> </i>0.293). The proportion of patients with American Society of Anesthesiologists (ASA) ≥ III, Nottingham hip fracture score (NHFS) ≥ 5 and preoperative activity tolerance < 4 metabolic equivalents (METs) increased sequentially (<i><i>P</i> </i>< 0.001), across the YO, MO, and OO groups, whereas the proportion of those with three or more internal medicine comorbidities sequentially decreased (<i><i>P</i> </i>< 0.001). …”

The Type I JAKinib, ruxolitinib, promotes pJAK1 and pJAK2 phosphorylation in MSCs from salivary glands. by Ilya Gurevic (1326786)

“…(E-G) were performed with replicates (n = 6; 3 SjD and 3 control) of our treatment conditions on the right with a representative western on the left; (E) pJAK1 proportion increased in a dose-dependent manner with increasing ruxolitnib; (F) pJAK2 proportion increased as ruxolitinib dose increased; (G) pSTAT1 decreased in a dose response relationship with increasing ruxolitinib. …”

Image3_A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever.jpeg by Saeko Yamada (11899439)

“…The patient had a remarkably low proportion of Naïve CD4 T cells. RNA-seq of peripheral blood immune cell subsets revealed significant differences in gene expression, especially in T cells.…”

Table 2_Outcomes after therapeutic SBE-ERCP for choledochojejunal/hepaticojejunal anastomotic stenosis after bile duct injury.docx by Yijun Shu (3456728)

“…Background<p>Choledochojejunal/hepaticojejunal anastomotic stenosis (CJS/HJS) is significant clinical problem associated with decreased survival postsurgery. …”

DataSheet1_A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever.docx by Saeko Yamada (11899439)

“…The patient had a remarkably low proportion of Naïve CD4 T cells. RNA-seq of peripheral blood immune cell subsets revealed significant differences in gene expression, especially in T cells.…”

Image 1_Effect of hypoxia-induced mIL15 expression on expansion and memory progenitor stem-like TILs in vitro.tif by Zhen Sun (269397)

“…Our experimental findings indicate that, compared to UN-TIL and TIL-mIL15+IL2 cells, the expression of mIL15 in TIL-mIL15-IL2 cells promoted the formation of stem-like TILs (CD8⁺CD39^-CD69^-) and led to significant decreases in the proportion and absolute number of terminally differentiated TILs (CD8⁺CD39⁺CD69⁺). …”

Table 3_Outcomes after therapeutic SBE-ERCP for choledochojejunal/hepaticojejunal anastomotic stenosis after bile duct injury.docx by Yijun Shu (3456728)

“…Background<p>Choledochojejunal/hepaticojejunal anastomotic stenosis (CJS/HJS) is significant clinical problem associated with decreased survival postsurgery. …”

Table 1_Outcomes after therapeutic SBE-ERCP for choledochojejunal/hepaticojejunal anastomotic stenosis after bile duct injury.docx by Yijun Shu (3456728)

“…Background<p>Choledochojejunal/hepaticojejunal anastomotic stenosis (CJS/HJS) is significant clinical problem associated with decreased survival postsurgery. …”

Image1_A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever.jpeg by Saeko Yamada (11899439)

“…The patient had a remarkably low proportion of Naïve CD4 T cells. RNA-seq of peripheral blood immune cell subsets revealed significant differences in gene expression, especially in T cells.…”

Image2_A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever.jpeg by Saeko Yamada (11899439)

“…The patient had a remarkably low proportion of Naïve CD4 T cells. RNA-seq of peripheral blood immune cell subsets revealed significant differences in gene expression, especially in T cells.…”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”